A Phase 3 interventional study of platelet-rich plasma and Corticosteroid in Knee Osteoarthritis, sponsored by Hospital Universitari Vall d'Hebron Research Institute. Completed at 1 site in Spain. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-02-24.
Sponsored by Hospital Universitari Vall d'Hebron Research Institute · Phase 3, Interventional, and Treatment
The benefit of using platelet rich plasma (PRP) in cartilage injuries, and specifically in degenerative ones, has not been assessed yet. Current studies on the PRP healing or repairing effect on knee cartilage degenerative injuries are not conclusive to establish a standard of behavior, although PRP has shown to improve joint functionality and reduce pain.
Hypothesis: PRP intra-articular injections in osteoarthritic knees reduces pain and leads to a more effective and lasting functional recovering than corticosteroid intra-articular injections.
4,397 studies on the registry are indexed under Osteoarthritis; 581 are open to participants now.
This study's enrollment of 74 is close to the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →Hospital Universitari Vall d'Hebron Research Institute is the lead sponsor of 268 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
a single intra-articular injection of PRP in knee osteoarthritis
Biological: platelet-rich plasma
a betamethasone and bupivacaine intra-articular injection
Drug: Corticosteroid
a single intra-articular injection
A single betamethasone and bupivacaine intra-articular injection
The value of the visual analogue scale pain (VAS)
The difference between the baseline and the value of the scale one month after treatment
Time frame: one month after the treatment
the value of pain visual analog scale according to
Time frame: 4 weeks, 3 and 6 months after treatment
the functional level of the knee KOOS
Time frame: 4 weeks, 3 and 6 months after treatment
All reported adverse events
Time frame: 4 weeks, 3 and 6 months after treatment
Scale of the SF36 quality of life
Time frame: 4 weeks, 3 and 6 months after treatment
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitari Vall d'Hebron Research Institute